Work

Tirzepatide (Mounjaro)-induced acute pancreatitis and ketoacidosis in an adult nondiabetic patient

Year: 2025

Type: article

Abstract: Tirzepatide (Mounjaro) is a new medication approved for type 2 diabetes and obesity treatment. It works by activating the receptors for both glucose-dependent insulinotropic peptide and glucagon-like peptide-1. Side effects due to tirzepatide are typically gastrointestinal in nature and self-resolving within a few days. Severe hypoglycemia, acute pancreatitis, or gallbladder disease are uncommon. We present the case of an adult nondiabetic patient who developed acute pancreatitis and ketoacidosis due to tirzepatide. Both are uncommon and serious adverse events of tirzepatide. Physicians should be aware of serious side effects due to tirzepatide as many nondiabetic patients take tirzepatide over the counter for weight loss. Tirzepatide should be prescribed under medical supervision.

Source: Saudi Journal for Health Sciences

DOI: 10.4103/sjhs.sjhs_122_24

Authors: Asma Ali Sallam, Bdoor Attaulla Alenezi, Muneerah M. Albugami

Institution: King Faisal Specialist Hospital & Research Centre

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4409619378

FWCI:

Cites: 5

Cited by:

Related to: 10